Liver‐Directing Fe(III)‐Based MRI Contrast Agent
Small · 2025
DOI: 10.1002/smll.202411465 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, 2025. Verfasst von Geetanjali Deka und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Indian Institute of Technology Guwahati, Guwahati, Assam, 781039, India. Hauptthemen laut MEDLINE: Contrast Media, Magnetic Resonance Imaging, Liver, Ferric Compounds. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 116 Literaturangaben. Gefördert von: FIST programme supported by DST, Department of Biotechnology, Department of Biotechnology, Government of West Bengal.
Abstract (Originalsprache)
Liver cancer has been identified as the second most common cause of cancer‐related mortality. Routine liver diagnosis by recording magnetic resonance (MR) images in the presence of a liver‐directing contrast agent (CA) can recognize any abnormalities early. However, the clinically approved liver‐specific Gd(III)‐based CAs are of great concern for bio‐safety. In fact, several medical agencies have restricted the usage of such CAs. Thus, to develop non‐Gd‐based biocompatible CAs for liver imaging, a thermodynamically stable and kinetically inert nonaquated six‐coordinate paramagnetic Fe(III)‐complex (1) is confined within a biocompatible porous silica nanoparticle of size about 18 nm. Such entrapment has boosted the longitudinal relaxivity value of Complex 1 ( r 1 = 0.59 × 10 −3 m −1 s −1 ) upto 9 times to 5.36 × 10 −3 m −1 s −1 , which further increased to 10.83 × 10 −3 m −1 s −1 in the presence of 0.67 × 10 −3 m concentration of serum albumin protein. Surface functionalization of the nanoparticle with hydrophobic p ‐methoxybenzamide ( C1 @SiO 2 ‐PMBA‐NP) facilitates HepG2 cell internalization as evinced by in vitro fluorescent images and flow cytometry analyses. Time‐dependent contrast changes in the liver MR images recorded on C57BL/6 mice in a preclinical MRI instrument establish the applicability of the biocompatible C1 @SiO 2 ‐PMBA‐NP as the T 1 ‐weighted liver‐directing CA for magnetic resonance imaging (MRI).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, Indian Institute of Technology Guwahati, Guwahati, Assam, 781039, India.
- Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, Guwahati, Assam, 781039, India.
- Department of NMR, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110029, India.
- Centre for Medical Biotechnology, Maharshi Dayanand University, Rohtak, Haryana, 124001, India.
ORCID-Profile: S Senthil Kumaran, Chandan Mukherjee
Förderung
- FIST programme supported by DST
- Department of Biotechnology
- Department of Biotechnology, Government of West Bengal
Zitieren
APA
Deka, G., Arora, A., Bhat, P., Singh, V., Mohan, H., Kumaran, S. S., & Mukherjee, C. (2025). Liver‐Directing Fe(III)‐Based MRI Contrast Agent. Small. https://doi.org/10.1002/smll.202411465
Vancouver
Deka G, Arora A, Bhat P, Singh V, Mohan H, Kumaran SS, et al. Liver‐Directing Fe(III)‐Based MRI Contrast Agent. Small. 2025. doi:10.1002/smll.202411465
BibTeX
@article{Deka2025,
author = {Deka, Geetanjali and Arora, Arisha and Bhat, Priyanka and Singh, Vandna and Mohan, Hari and Kumaran, S Senthil and Mukherjee, Chandan},
title = {Liver‐Directing Fe(III)‐Based MRI Contrast Agent},
journal = {Small},
year = {2025},
doi = {10.1002/smll.202411465}
}
EUVIMED